Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Oracle Corporation (ORCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Oracle Corporation — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Oracle Corporation trades at $128.04 (market cap $434.11B). The key difference: Oracle Corporation is far larger — about 151.8× Dyne Therapeutics Inc. Common Stock's market cap, and Oracle Corporation pays a 1.4% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Oracle Corporation for 73 Days on average.
| DYN | ORCL | |
|---|---|---|
Market Cap | $2.86B | $434.11B |
Volume | 3,341,579 | 25,917,551 |
Sector | Health | Technology |
52-Week High | $26.78 | $313.00 |
52-Week Low | $14.60 | $114.99 |
Typical Hold Time | 0 Days | 73 Days |
Enterprise Value | $2.18B | $557.92B |
Dividend Yield | — | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Oracle (ORCL) trades at $137.40, down 2.92% on the day amid a bearish technical signal, though it has consistently beaten earnings estimates in recent quarters. Revenue grew to $57.40B in 2025 with a net income margin of 26.36%, while analyst consensus remains strongly bullish with a $236.52 price target. Recent news highlights strong AI cloud demand and restructuring efforts to support growth.
The outlook is positive given robust fundamentals and AI-driven revenue acceleration, but risks include high debt levels, competitive pressures, and market volatility. The stock presents a long-term opportunity if execution on AI infrastructure continues, though near-term price weakness reflects investor caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
